Integrating Chronic Disease Management and Harm Reduction for Youth with Juvenile Idiopathic Arthritis Amid Canada’s Overdose Crisis

Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition in children that often requires long-term pain management, which can include opioid use. In the context of Canada's ongoing overdose crisis, youth with JIA face risks due to potential opioid dependency and exposure to toxic drug supplies. This commentary proposes an integrated approach combining chronic disease management with harm reduction strategies specifically tailored for JIA patients. By incorporating multidisciplinary care, opioid stewardship, and harm reduction measures, this approach aims to address the dual challenges of managing chronic pain and mitigating substance use risks. Key recommendations include the development of integrated care models, enhanced access to multidisciplinary services, allocation of resources for specialized pain management, research, and mental health support, and investment in harm reduction initiatives. Additionally, comprehensive training for healthcare providers on the intersection of chronic pain, substance use, and mental health is essential. This integrated strategy not only supports the medical and psychosocial needs of youth with JIA but also offers a model for addressing the broader challenges faced by vulnerable populations in the overdose crisis. Adopting these measures will help protect this at-risk group, improve their quality of life, and contribute to the overall public health response to the overdose epidemic.